Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPC-003 in Recurrent or Refractory Glioblastoma
NCT07193628Phase 1Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of EPC-003 in glioblastoma (GBM) (4 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence of grade 3-4 adverse events related to B7H3/IL13Ra2 CAR-T therapy at 28 days. Started Sep 2025; status: recruiting.
02
Drugs
EPC-003
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07193628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193628.